Sensorineural hearing loss in patients with head and neck cancer after chemoradiotherapy and radiotherapy: A systematic review of the literature

Theunissen, Eleonoor A. R.; Bosma, Sophie C J; Zuur, Charlotte L.; Spijker, René; Baan, S. Van Der; Dreschler, Wouter A.; Boer, Jan Paul de; Balm, Alfons J. M.; Rasch, Coen R. N.

doi:10.1002/hed.23551

Cited by 83 publications

(85 citation statements)

References 64 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Its incidence is increased to 17–88% when RT is combined with cisplatin [178]. Traditionally, SNHL denotes a pure-tone audiometry confirmed, clinically significant increase in bone conduction threshold at the key human speech frequencies (0.5–4.0 kHz) [179].…”

Section: Hearing Lossmentioning

confidence: 99%

“…Early changes in hearing could be reversible, though the probability of clinically relevant threshold deterioration of hearing increases over time, with the median latency period being 1.5 to 2 years [181,182]. In addition to a radiation dose of 47 Gy or more to the cochlea, the main factors affecting the risk of SNHL are the patient’s age and baseline hearing level, cisplatin dose, post-RT otitis media, and follow-up time [178,179,183–185]. In addition, the deterioration in air conduction caused by RT-induced Eustachian tube dysfunction and middle air fibrosis may accompany persistent SNHL, indicating mixed hearing impairment [186].…”

Section: Hearing Lossmentioning

confidence: 99%

See 1 more Smart Citation

Treatment of late sequelae after radiotherapy for head and neck cancer

Strojan

Hutcheson

Eisbruch

et al. 2017

Cancer Treatment Reviews

254

171

View full text Add to dashboard Cite

Radiotherapy (RT) is used to treat approximately 80% of patients with cancer of the head and neck. Despite enormous advances in RT planning and delivery, a significant number of patients will experience radiation-associated toxicities, especially those treated with concurrent systemic agents. Many effective management options are available for acute RT-associated toxicities, but treatment options are much more limited and of variable benefit among patients who develop late sequelae after RT. The adverse impact of developing late tissue damage in irradiated patients may range from bothersome symptoms that negatively affect their quality of life to severe life-threatening complications. In the region of the head and neck, among the most problematic late effects are impaired function of the salivary glands and swallowing apparatus. Other tissues and structures in the region may be at risk, depending mainly on the location of the irradiated tumor relative to the mandible and hearing apparatus. Here, we review the available evidence on the use of different therapeutic strategies to alleviate common late sequelae of RT in head and neck cancer patients, with a focus on the critical assessment of the treatment options for xerostomia, dysphagia, mandibular osteoradionecrosis, trismus, and hearing loss.

show abstract

Section: Hearing Lossmentioning

confidence: 99%

Section: Hearing Lossmentioning

confidence: 99%

Treatment of late sequelae after radiotherapy for head and neck cancer

Strojan

Hutcheson

Eisbruch

et al. 2017

Cancer Treatment Reviews

254

171

View full text Add to dashboard Cite

show abstract

“…Most studies on cisplatin‐induced ototoxicity in LAHNC have been performed in patients treated with high‐dose cisplatin, that is, 100 mg/m 2 on days 1, 22, and 43 . The incidence of sensorineural hearing loss after chemoradiotherapy in LAHNC patients is 17%‐88% . This wide range is due to heterogeneity of the population, different definitions of ototoxicity, and different treatment schedules.…”

Section: Introductionmentioning

confidence: 99%

Ototoxicity in locally advanced head and neck cancer patients treated with induction chemotherapy followed by intermediate or high‐dose cisplatin‐based chemoradiotherapy

Driessen¹,

Leijendeckers

Snik

et al. 2018

Head & Neck

View full text Add to dashboard Cite

Background This study evaluated ototoxicity in locally advanced head and neck cancer patients treated in the CONDOR study with docetaxel/cisplatin/5‐fluorouracil (TPF) followed by conventional radiotherapy with concomitant cisplatin 100 mg/m2 on days 1, 22, and 43 (cis100+RT) versus accelerated radiotherapy with concomitant cisplatin weekly 40 mg/m2 (cis40+ART). Methods Sixty‐two patients were treated in this study. Audiometry was performed at baseline, during TPF, before start of chemoradiotherapy, and 1, 4, 8, and 12 months after treatment. Results A complete dataset of audiometric data was available of 12 patients treated with high‐dose cisplatin and of 11 patients treated with intermediate‐dose cisplatin. Patients in the high‐dose group showed significant more hearing loss than in the intermediate group at 4 kHz ([z = 1.98; P = .04] and 8 kHz [z = 2.07; P < .03]). Interindividual variation was high in both groups. Conclusion After induction TPF, more ototoxicity was observed in chemoradiotherapy with cis100+RT than after chemoradiotherapy with cis40+ART.

show abstract

“…Patients often have tinnitus, dizziness, and other symptoms. Hearing loss and related symptoms seriously impact patients' daily lives, leading to anxiety, low self‐esteem, depression, and other psychological problems . The prevention of hearing loss after radiotherapy has important clinical significance for patients with nasopharyngeal carcinoma.…”

Section: Introductionmentioning

confidence: 99%

Methylprednisolone use during radiotherapy extenuates hearing loss in patients with nasopharyngeal carcinoma

et al. 2015

View full text Add to dashboard Cite

show abstract

Sensorineural hearing loss in patients with head and neck cancer after chemoradiotherapy and radiotherapy: A systematic review of the literature

Abstract: The wide range of SNHL incidence rates makes it impossible to draw any conclusions on the severity of RT- and CRT-induced ototoxicity. To allow for future comparison of study outcomes, development of uniform criteria is of utmost importance.

Cited by 83 publications

References 64 publications

Treatment of late sequelae after radiotherapy for head and neck cancer

Treatment of late sequelae after radiotherapy for head and neck cancer

Ototoxicity in locally advanced head and neck cancer patients treated with induction chemotherapy followed by intermediate or high‐dose cisplatin‐based chemoradiotherapy

Methylprednisolone use during radiotherapy extenuates hearing loss in patients with nasopharyngeal carcinoma

Contact Info

Product

Resources

About